期刊
BLOOD
卷 109, 期 4, 页码 1653-1659出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2006-04-015537
关键词
-
类别
资金
- NCI NIH HHS [R01 CA106258, R01CA106258] Funding Source: Medline
- NCRR NIH HHS [PZ0 RR016443, P20 RR016443] Funding Source: Medline
Adult T-cell leukemia (ATL) is an aggressive lymphoproliferative disease of poor clinical prognosis associated with infection by the human T-cell leukemia virus type I (HTLV-1). The use of arsenic trioxide (AS(2)O(3)) has been shown to effectively treat acute promyelocytic leukemia (APL) with greater than 80% of patients achieving complete remission. The combination of arsenic and interferon has also shown promising results in the treatment of ATL. The requirement for slow dosage increases of arsenic and the time required to achieve a pharmacologic active dose in patients is a major obstacle because median survival of patients with ATL is about 6 months. In this study we report a potent synergistic effect of the combination of arsenic trioxide and interferon alpha (As/IFN-ci) with emodin and DHA on cell-cycle arrest and cell death of HTLV-1-infected cells. Importantly, we found that clinically achievable doses of DHA and emodin allowed for reduced arsenic concentrations by 100-fold while still remaining highly toxic to tumor cells. Our data provide a rationale for combined use of As/IFN-alpha with emodin and DHA in patients with ATL refractory to conventional therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据